NASDAQ:QGEN - Qiagen Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$36.66 +0.45 (+1.24 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$36.66
Today's Range$36.49 - $36.80
52-Week Range$30.20 - $37.61
Volume1.38 million shs
Average Volume1.00 million shs
Market Capitalization$7.77 billion
P/E RatioN/A
Dividend YieldN/A
Qiagen logoQIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Receive QGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryLife Sciences Tools & Services


Debt-to-Equity Ratio0.69
Current Ratio5.07
Quick Ratio4.59


Trailing P/E RatioN/A
Forward P/E Ratio27.36
P/E Growth1.93

Sales & Book Value

Annual Sales$1.42 billion
Price / Sales5.90
Cash Flow$2.7095 per share
Price / Cash13.53
Book Value$11.13 per share
Price / Book3.29


EPS (Most Recent Fiscal Year)N/A
Net Income$40.39 million
Net Margins2.85%
Return on Equity11.74%
Return on Assets6.28%


Outstanding Shares228,230,000

The Truth About Cryptocurrencies

Qiagen (NASDAQ:QGEN) Frequently Asked Questions

What is Qiagen's stock symbol?

Qiagen trades on the NASDAQ under the ticker symbol "QGEN."

How will Qiagen's stock buyback program work?

Qiagen declared that its Board of Directors has approved a share buyback plan on Thursday, February 1st 2018, which authorizes the company to repurchase $200,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are often an indication that the company's board believes its shares are undervalued.

How were Qiagen's earnings last quarter?

Qiagen NV (NASDAQ:QGEN) issued its earnings results on Wednesday, May, 2nd. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.02. The business earned $343.60 million during the quarter, compared to analysts' expectations of $339.30 million. Qiagen had a net margin of 2.85% and a return on equity of 11.74%. Qiagen's revenue for the quarter was up 11.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.22 earnings per share. View Qiagen's Earnings History.

When is Qiagen's next earnings date?

Qiagen is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Qiagen.

What guidance has Qiagen issued on next quarter's earnings?

Qiagen issued an update on its FY18 earnings guidance on Wednesday, May, 2nd. The company provided earnings per share guidance of $1.31-$1.33 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.35. The company issued revenue guidance of $1.50-$1.52, compared to the consensus revenue estimate of $1.55 billion.Qiagen also updated its Q2 guidance to $0.31-$0.32 EPS.

What price target have analysts set for QGEN?

14 brokers have issued 12-month target prices for Qiagen's stock. Their forecasts range from $28.00 to $40.00. On average, they expect Qiagen's share price to reach $35.20 in the next twelve months. View Analyst Ratings for Qiagen.

Who are Qiagen's key executives?

Qiagen's management team includes the folowing people:
  • Manfred E. Karobath, Chairman of the Supervisory Board (Age 76)
  • Peer M. Schatz, Chief Executive Officer, Managing Director
  • Roland Sackers, Chief Financial Officer
  • Thomas Schweins, Senior Vice President - Human Resources, Strategy & Marketing Services
  • Thierry Bernard, Senior Vice President - Molecular Diagnostics Business Area
  • Laura Furmanski, Senior Vice President - Bioinformatics Business Area
  • Douglas Liu, Senior Vice President - Global Operations
  • Manuel O. Mendez, Senior Vice President - Global Commercial Operations
  • Stephane Bancel, Independent Supervisory Director (Age 44)
  • Hakan Bjorklund, Supervisory Board Director (Age 61)

Has Qiagen been receiving favorable news coverage?

Media headlines about QGEN stock have trended somewhat positive on Saturday, according to Accern Sentiment. The research firm ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Qiagen earned a daily sentiment score of 0.12 on Accern's scale. They also assigned news articles about the company an impact score of 46.00 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Qiagen's major shareholders?

Qiagen's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (8.15%), Massachusetts Financial Services Co. MA (5.10%), BlackRock Inc. (2.11%), Frontier Capital Management Co. LLC (1.08%), Legal & General Group Plc (0.97%) and Manning & Napier Group LLC (0.97%). View Institutional Ownership Trends for Qiagen.

Which major investors are selling Qiagen stock?

QGEN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Platinum Investment Management Ltd., Manning & Napier Group LLC, Point72 Asset Management L.P., Millennium Management LLC, Franklin Resources Inc., Van ECK Associates Corp and Systematic Financial Management LP. View Insider Buying and Selling for Qiagen.

Which major investors are buying Qiagen stock?

QGEN stock was bought by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Citadel Advisors LLC, Legal & General Group Plc, Carmignac Gestion, Sandler Capital Management, Neuberger Berman Group LLC, Seven Eight Capital LP and Tikvah Management LLC. View Insider Buying and Selling for Qiagen.

How do I buy shares of Qiagen?

Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Qiagen's stock price today?

One share of QGEN stock can currently be purchased for approximately $36.66.

How big of a company is Qiagen?

Qiagen has a market capitalization of $7.77 billion and generates $1.42 billion in revenue each year. Qiagen employs 4,684 workers across the globe.

How can I contact Qiagen?

Qiagen's mailing address is Hulsterweg 82, VENLO, 5912 PL, Netherlands. The company can be reached via phone at +31-77-3556600 or via email at [email protected]

MarketBeat Community Rating for Qiagen (QGEN)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  296 (Vote Outperform)
Underperform Votes:  401 (Vote Underperform)
Total Votes:  697
MarketBeat's community ratings are surveys of what our community members think about Qiagen and other stocks. Vote "Outperform" if you believe QGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.